Atomo NewsGet the app

Get the latest Science News and Discoveries

Phase III ARTEMIS-008 trial shows risvutatug rezetecan significantly improves overall survival in relapsed small-cell lung cancer


None

Get the Android app

Or read this on Eureka Alert

Read more on:

Photo of overall survival

overall survival

Photo of cell lung cancer

cell lung cancer

Photo of risvutatug rezetecan

risvutatug rezetecan

Related news:

News photo

Late-breaking HARMONi-2 analysis shows ivonescimab significantly improves overall survival versus pembrolizumab in PD-L1-Positive Advanced NSCLC

News photo

Phase III ARTEMIS-008 trial shows risvutatug rezetecan significantly improves overall survival in relapsed small-cell lung cancer

News photo

Phase III MAVERICK trial supports brain MRI surveillance alone as standard of care for small-cell lung cancer

« In the PAPILLON study, first-line amivantamab-chemotherapy demonstrates the longest overall survival reported for EGFR exon 20 insertion-positive advanced NSCLC
Sacituzumab govitecan plus pembrolizumab does not meet primary endpoints in first-line PD-L1-high metastatic NSCLC »